• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>GlaxoSmithKline PLC ADR

GlaxoSmithKline PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. FDA Approves Flonase® Allergy Relief For Sale Over-The-Counter In The United States

    FDA Approves FlonaseĀ® Allergy Relief For Sale Over-The-Counter In The United States

  2. ADR Shares End Mixed; GlaxoSmithKline Shares Trade Actively

    ADR Shares End Mixed; GlaxoSmithKline Shares Trade Actively

  3. UPDATE: Intuitive Surgical soars on earnings; Xilinx sinks

    UPDATE: Intuitive Surgical soars on earnings; Xilinx sinks

  4. UPDATE: Glaxo slides in London after earnings warning

    UPDATE: Glaxo slides in London after earnings warning

  5. Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program

    Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program

  6. China charges foreign investigators linked to Glaxo case

    China charges foreign investigators linked to Glaxo case

  7. Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022

    Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022

  8. Research and Markets: Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

    Research and Markets: Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  9. Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022

    Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022

  10. Research and Markets: Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

    Research and Markets: Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.